TABLE 2.

Baseline characteristics of randomized-controlled trials on short DAPT following ticagrelor monotherapy.

Study	n	Bleeding and ischemic risk	Ethnicity	Clinical setting (%)		DAPT duration	Follow-up (months)	Primary endpoint	Primary endpoint met
				ACS	CCS
GLOBAL-LEADERS	15,968	Low bleeding risk, mixed ischemic risk*	Caucasian	47	53	1 vs. 12 months	24	All-cause death, MI	NO
TWILIGHT	7,119	Low bleeding risk, mixed ischemic risk	Caucasian East Asian	64	36	3 vs. 12 months	15	BARC type 2,3, or 5	Yes
TICO	3,056	Low bleeding risk, mixed ischemic risk	East Asian	100	0	3 vs. 12 months	12	TIMI major bleeding, all-cause death, MI, ST, stroke, or TVR	Yes

n, number of patients; ACS, acute coronary syndrome; CCS, chronic coronary syndrome; DAPT, dual antiplatelet therapy; MI, Myocardial infarction; BARC, Bleeding Academic Research Consortium; TIMI, Thrombolysis in Myocardial Infarction; ST, stent thrombosis; TVR, target vessel revascularization. *Mixed ischemic risk includes low, moderate and high ischemic risk.